Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
Orion's license partner, Tenax Therapeutics, announced that its Phase 3 LEVEL trial for oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not meet its primary endpoint of improved 6-minute walk distance. However, subgroup analyses showed a beneficial …